EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

P21, p27 and p53 in estrogen and antiprogestin-induced tumor regression of experimental mouse mammary ductal carcinomas



P21, p27 and p53 in estrogen and antiprogestin-induced tumor regression of experimental mouse mammary ductal carcinomas



Carcinogenesis (Oxford) 23(5): 749-757



Metastatic mammary carcinoma tumor lines 59-2-HI and C7-2-HI originated in female BALB/c mice treated with medroxyprogesterone acetate and are maintained by syngeneic transplantation. Both lines express estrogen (ER) and progesterone receptors (PR) and regress completely after estradiol (E2) or antiprogestin treatment. The BET tumor line, of similar origin and biological features, regresses only after E2 treatment. To investigate possible differences between E2- and antiprogestin-mediated effects we evaluated the morphological features, mitosis and apoptosis, and the differential expression of cell-cycle inhibitors associated with tumor regression. Treatments started when tumors reached 50-100 mm2. After 24-96 h, tumors were excised and processed for morphological and immunohistochemical studies. Regression was associated with a significant and early decrease in the number of mitosis and with higher percentages of apoptotic cells. These phenomena were accompanied by an increase in p21 and p27 expression in the E2 and antiprogestin-responsive lines treated with E2, RU 38.486 or ZK 98.299 (P < 0.05). In BET tumors treated with E2, p21 expression remained within basal levels and only p27 increased (P < 0.05). p53 was low in control 59-2-HI and C7-2-HI tumors and increased after treatment (P < 0.05) whereas BET untreated tumors already expressed high levels of p53 and MDM2. Although the immunohistochemical findings were compatible with alterations of p53, SSCP evaluation failed to disclose the presence of mutations, suggesting that the defective expression of p21 is related to an impaired p53 pathway. UV irradiation failed to increase p21 expression in BET, but was able to induce p53 and p21 in 59-2-HI and C7-2-HI tumors. The absence of an increased expression of p21 in E2-regressing BET lesions suggests that this protein is not necessary for estrogen-induced regression, but may be essential for antiprogestin action. Our results also suggest that p53/MDM2 alterations may be one of the mechanisms responsible for selected hormone resistance in breast carcinomas.

(PDF emailed within 0-6 h: $19.90)

Accession: 011666807

Download citation: RISBibTeXText

PMID: 12016147

DOI: 10.1093/carcin/23.5.749



Related references

Genetic control of ductal morphology, estrogen-induced ductal growth, and gene expression in female mouse mammary gland. Endocrinology 155(8): 3025-3035, 2014

Hypermethylation of the progesterone receptor A in constitutive antiprogestin-resistant mouse mammary carcinomas. Breast Cancer Research and Treatment 126(2): 319-332, 2011

Interleukin-12 inhibits angiogenesis and growth of transplanted but not in situ mouse mammary tumor virus-induced mammary carcinomas. Cancer Research 62(3): 747-755, 2002

Estrogen or antiprogestin treatment induces complete regression of pulmonary and axillary metastases in an experimental model of breast cancer progression. Carcinogenesis 26(6): 1055-1063, 2005

Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer. Breast Cancer Research 13(1): R11-R11, 2014

Lack of ductal development in the absence of functional estrogen receptor alpha delays mammary tumor formation induced by transgenic expression of ErbB2/neu. Cancer Research 62(10): 2798-2805, 2002

Studies on the mouse mammary tumor agent mta part 2 cytochemistry of amino peptidase in normal mammary gland of c 57 bl spontaneous and virus induced mammary tumors in r 111 and c 57 bl mouse strains respectively and in cell lines producing the mammary tumor virus. Acta Histochemica: 181-188, 1970

Quantification of mouse mammary tumor virus structural proteins in hormone-induced mammary tumors of low mammary tumor mouse strains. International Journal of Cancer 25(3): 377-383, 1980

The different activation of int genes in mammary carcinomas developed in three mouse strains harboring mouse mammary tumor viruses derived from DD/Tbr. Jikken Dobutsu. Experimental Animals 40(4): 431-438, 1991

Estrogen inhibition of MPA-induced mouse mammary tumor transplants. International Journal of Cancer 49(6): 900-905, 1991

Loss of p21WAF1/CIP1 results in delayed FTI-2148-induced mammary tumor regression and accelerated tumor regrowth after FTI removal in an oncogenic H-ras transgenic mouse model. Proceedings of the American Association for Cancer Research Annual Meeting 42: 487, March, 2001

Involvement of mouse mammary tumor virus in spontaneous and hormone-induced mammary tumors in low-mammary-tumor mouse strains. Journal of Virology 27(3): 551-559, 1978

Mouse mammary tumor virus genome expression in chemical carcinogen induced mammary tumors in low tumor and high tumor incidence mouse strains. Proceedings of the National Academy of Sciences of the United States of America 76(10): 5360-5264, 1979

Experimental radiation therapy of spontaneous mouse mammary tumor in situ radio sensitivity of mammary tumor cells as compared with 3 methyl cholanthrene induced fibro sarcoma cells. Journal of Radiation Research 22(1): 43-44, 1981

Concerted activation of two potential proto oncogenes in carcinomas induced by mouse mammary tumor virus. Nature (London) 320(6063): 628-631, 1986